SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corp. (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that its development partner Wyeth (NYSE:WYE) presented preliminary scientific data on an investigational DNA vaccine for HIV, including results from a non-human primate study, using one of Inovio’s proprietary DNA delivery systems. This presentation took place at the Vaccines - Linking Vaccine Development with Market Opportunities conference held in Brussels, Belgium, February 15 - 16, 2007.
